Ligand Pharmaceuticals
LGND Nasdaq· Biotechnology
Last close · Oct 27, 2026
$311.73
KIRA · Stoqly’s AI analyst, in plain words
- Ligand Pharmaceuticals had $268M of revenue in fiscal 2025, up 60.4% on the year before. Over five years, revenue changed +10.4% a year on average.
- Its operating margin was 15.3%, up 28.8 pts: of every 100 in sales, about 15 is left after running the business.
- Ligand Pharmaceuticals made $125M of net profit in fiscal 2025.
- Free cash flow was $48.9M in fiscal 2025, 18.2% of revenue.
- Ligand Pharmaceuticals returned $15.0M to shareholders in fiscal 2025, 31% of free cash flow. The diluted share count rose 11.0%.
- Ligand Pharmaceuticals has $287M more cash than debt.
Market cap
$6.8B
P/E
33.1x
Revenue
$268M
Net income
$125M
Free cash flow
$48.9M
Operating margin
15.3%
Ligand Pharmaceuticals in 30 seconds · fiscal 2025
Are sales growing?
+60.4%
Yes. Sales grew 60.4% last year.
Does it make a profit?
46.4%
Yes. It keeps 46.4% of every sale as profit.
Does profit turn into cash?
18.2%
Yes. 18.2% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
33.1x
One share costs 33.1 times its yearly profit per share. Typical for its sector: 27.9x.
What Ligand Pharmaceuticals does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- LIGAND PHARMACEUTICALS INCORPORATED
- CIK
- 0000886163
Ligand Pharmaceuticals · LGND
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $242M | $196M | $131M | $167M | $268M |
| Revenue growth | 47.7% | −18.8% | −33.1% | 27.3% | 60.4% |
| Operating margin | 43.0% | 1.6% | 9.1% | −13.5% | 15.3% |
| Net income | $57.1M | −$33.4M | $52.2M | −$4.0M | $125M |
| Net margin | 23.7% | −17.0% | 39.7% | −2.4% | 46.4% |
| Diluted EPS | $3.31 | −$1.98 | $2.94 | −$0.22 | $6.13 |
| Cash | |||||
| Cash from operations | $78.8M | $138M | $49.6M | $97.0M | $49.4M |
| Capital expenditure | $8.8M | $17.9M | $3.5M | $1.8M | $0.5M |
| Free cash flow | $70.0M | $120M | $46.1M | $95.2M | $48.9M |
| FCF margin | 29.0% | 61.1% | 35.1% | 57.0% | 18.2% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $15.0M |
| Share count change | 2.5% | −2.2% | 5.3% | 3.0% | 11.0% |
| Debt and strength | |||||
| Cash and short-term investments | $341M | $212M | $170M | $256M | $734M |
| Debt incl. finance leases | $321M | $76.7M | $0.0M | $0.1M | $446M |
| Shareholders' equity | $821M | $598M | $701M | $830M | $1.0B |
| Net debt / EBITDA | −0.1x | −2.5x | −3.5x | −20.3x | −3.8x |
| Current ratio | 11.2x | 2.7x | 14.2x | 8.9x | 22.2x |
| Interest coverage | 5.3x | 1.7x | 18.2x | −7.4x | 8.7x |
| Returns and quality | |||||
| Return on capital | 13.4% | 0.2% | 2.0% | −2.1% | 4.9% |
| Return on equity | 7.5% | −4.7% | 8.0% | −0.5% | 13.5% |
| Piotroski F-score | 7 | 4 | 6 | 3 | 5 |
| Altman Z'' | 5.6 | 7.2 | 12.6 | 11.5 | 6.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$34.7M
9 insiders
Of sales under plans
69%
$24.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ligand Pharmaceuticals · LGND
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Ligand Pharmaceuticals LGND | $6.8B | 60.4% | 15.3% | 18.2% | 4.9% | 33.1x | 5 |
| Krystal Biotech KRYS | $9.8B | 33.9% | 41.5% | 48.6% | 43.6% | 40.2x | 5 |
| ADMA Biologics ADMA | $2.6B | 19.6% | 37.5% | 5.5% | 39.5% | 16.0x | 5 |
| Repligen RGEN | — | 16.4% | 7.5% | 12.7% | 2.4% | — | — |
| Cytokinetics CYTK | — | 376.6% | −695.4% | −607.5% | — | — | — |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $311.73 a share, the company is worth $6.8B: 33.1 times its earnings of the last four quarters.
Ligand Pharmaceuticals grew sales faster than 3 of its 4 similar companies. Its P/E is higher than 1 of 2.
Source: SEC EDGAR XBRL filings (CIK 0000886163). Data updated October 22, 2026. For information only — not investment advice. Check the original filings before relying on any figure.